CD274 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) antibodies, have achieved durable responses in some patients with non-small-cell lung cancer (NSCLC) (1–6).